EcoDrugPlus

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSPEMG00000022207
Gene Symbol: MAPK11
3 Cross references
200 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSPEMG00000016661
Gene Symbol: MAPK14
3 Cross references
281 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSPEMG00000001609
Gene Symbol: MAPK3
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSPEMG00000012207
Gene Symbol: MAPK8
3 Cross references
294 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSPEMG00000016205
Gene Symbol: MAPK9
3 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSPEMG00000007282
Gene Symbol: MAP2K1
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSPEMG00000021952
Gene Symbol: MAP2K2
1 Cross references
261 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSPEMG00000023508
Gene Symbol: MAP3K1
1 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSPEMG00000009761
Gene Symbol: MAP3K10
3 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSPEMG00000018188
Gene Symbol: MAP3K11
3 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSPEMG00000000990
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSPEMG00000014973
Gene Symbol: MAP3K13
3 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).